In type 2 diabetes with increased CV risk, tirzepatide reduced HbA<sub>1c</sub> vs. glargine at 52 wk.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35226523.
- Also identified by DOI 10.7326/J22-0009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Del Prato S, Kahn SE, Pavo I, et al. <b>Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.</b> Lancet. 2021;398:1811-24. 34672967.
Medical subject headings
- Diabetes Mellitus, Type 2